首页> 外文期刊>Journal of peptide science: An official publication of the European Peptide Society >Influenza A virus protein PB1-42: synthesis and characterization of the biologically active full length protein and related peptides
【24h】

Influenza A virus protein PB1-42: synthesis and characterization of the biologically active full length protein and related peptides

机译:甲型流感病毒蛋白PB1-42:具有生物学活性的全长蛋白和相关肽的合成和表征

获取原文
获取原文并翻译 | 示例
       

摘要

Recently the discovery of a novel 87 amino acid influenza A virus (IAV) protein, named PB1-F2, has been reported that originates from an alternative reading frame in the PB1 polymerase gene and is encoded in most of the known human IAV isolates. Using optimized protocols, full length biologically active sPB1-F2 and a number of fragments have been synthesized by following either the standard elongation SPPS method or by native chemical ligation of unprotected N- and C-terminal peptide fragments at the histidine and cysteine residues located in position 41 and 42 of the native sequence, respectively. The ligation procedure afforded the most efficient synthesis of sPB1-F2 and facilitated the generation of various mutants of sPB1-F2 from pre-synthesized peptide fragments. During the synthesis of sPB1-F2, the formation of succinimide and subsequent conversion to the piperidine derivative at the aspartic acid residue in position 23 was observed. This reaction was forestalled by applying specific modifications to the SPPS protocol. The chain-elongation SPPS protocol is optimal for producing small peptides of sPB1-F2, their derivatives and precursors for a subsequent ligation protocol, while the full length protein, mutants and labelled derivatives are more conveniently and efficiently synthesized by SPPS protocols that include native chemical ligation. The molecular identity of sPB1-F2 was confirmed by peptide mapping, mass spectrometry, N-terminal sequencing, H-1 NMR spectroscopy and Western blot analysis. The latter analysis afforded direct evidence of the inherent tendency of sPB1-F2 to undergo oligomerization, a phenomenon observed both for full length sPB1-F2 and fragments thereof, as well as for its full length viral counterpart. Our synthesis protocols open the field for multiple biological and structural studies on sPB1-F2 that, similar to the molecule expressed in an IAV context, induces apoptosis and interacts with membranes in vitro and in vivo, as shown in previous studies. Copyright (c) 2005 European Peptide Society and John Wiley & Sons, Ltd.
机译:最近,已经报道了一种名为PB1-F2的新型87氨基酸甲型流感病毒(IAV)蛋白的发现,该蛋白起源于PB1聚合酶基因中的替代阅读框,并在大多数已知的人IAV分离株中编码。使用优化的方案,已通过遵循标准延伸SPPS方法或通过天然化学连接未保护的N和C端肽片段在组氨酸和半胱氨酸残基上的全长生物活性sPB1-F2和许多片段来合成。天然序列的第41位和第42位。连接过程提供了最有效的sPB1-F2合成,并促进了从预先合成的肽片段生成sPB1-F2的各种突变体。在合成sPB1-F2的过程中,观察到琥珀酰亚胺的形成和随后在位置23的天冬氨酸残基上转化为哌啶衍生物的现象。通过对SPPS协议进行特定的修改来阻止此反应。链延长SPPS方案最适合用于生产sPB1-F2的小肽,其衍生物和前体以用于随后的连接方案,而全长蛋白,突变体和标记衍生物可以通过SPPS方案(包括天然化学物质)更方便有效地合成结扎。 sPB1-F2的分子身份已通过肽谱分析,质谱,N端测序,H-1 NMR光谱和Western印迹分析得到了证实。后面的分析提供了sPB1-F2固有的低聚趋势的直接证据,这种现象在全长sPB1-F2及其片段以及全长病毒对应物中均观察到。我们的合成方案为sPB1-F2的多个生物学和结构研究开辟了领域,与先前在IAV中表达的分子相似,它可以在体外和体内诱导凋亡并与膜发生相互作用。版权所有(c)2005欧洲肽协会和John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号